Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

Cellular & Molecular Immunology is a prestigious peer-reviewed journal published by the CHIN SOCIETY IMMUNOLOGY. As a leading journal in the fields of immunology and infectious diseases, it proudly holds a Q1 designation across multiple categories, including Immunology, Allergy, and Medicine (Miscellaneous), reflecting its commitment to excellence and impactful research. With an ISSN of 1672-7681 and an E-ISSN of 2042-0226, the journal has been essential reading since its inception in 2004, continuously gathering insights from cutting-edge studies. It ranks impressively within Scopus, with positions in the 7th, 8th, and 9th percentile in relevant categories, establishing it as a cornerstone for researchers, clinicians, and students alike. The journal offers an extensive range of original research articles, reviews, and clinical studies, ensuring that readers stay at the forefront of immunological discovery. Whether you are interested in basic immunology, infectious diseases, or evolving therapies, Cellular & Molecular Immunology serves as an invaluable resource for advancing your knowledge and engagement in this dynamic field.

Innate Immunity, published by SAGE Publications Ltd, serves as a vital platform for disseminating cutting-edge research in the fields of immunology, microbiology, cell biology, and infectious diseases. With an ISSN of 1753-4259 and an E-ISSN of 1753-4267, this journal has been a prominent contributor to the academic community since its inception in 1996, focusing on the innate immune response and its implications for health and disease. Holding a respectable impact factor and categorized in the Q2 and Q3 quartiles across various relevant domains, Innate Immunity ranks competitively in major databases, including Scopus, where it appears in the top 75th percentile for Infectious Diseases. Researchers and professionals are encouraged to explore its wealth of articles that are pivotal in bridging fundamental immunology with clinical applications, fostering a deeper understanding of immune mechanisms vital for combating human diseases.

NATURE IMMUNOLOGY is a premier academic journal published by NATURE PORTFOLIO, dedicated to advancing the field of immunology. With an impressive impact factor that reflects its esteemed position, this journal ranks in the top quartile (Q1) of renowned categories, including Immunology and Allergy. Serving as a crucial platform for researchers, professionals, and students, NATURE IMMUNOLOGY showcases cutting-edge research, comprehensive reviews, and insightful perspectives that drive innovation in immunological science. Based in the United Kingdom, this journal has been a vital contributor to the global discourse on immune responses and related diseases since its inception in 2000. Researchers can benefit from its rigorous peer-review process, ensuring that only high-quality studies are disseminated, thus enhancing their academic pursuits and practical applications. Explore the latest findings and trends within this flourishing discipline, making NATURE IMMUNOLOGY an essential resource for anyone engaged in the study of the immune system.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

INFLAMMATION RESEARCH, published by SPRINGER BASEL AG, serves as a pivotal journal in the fields of Immunology and Pharmacology, with notable rankings of Q2 in Immunology and Q1 in Pharmacology as of 2023. With an ISSN of 1023-3830 and an E-ISSN of 1420-908X, this esteemed journal, located in Basel, Switzerland, has been at the forefront of advancing our understanding of inflammatory processes since its inception in 1995. Covering research trends and breakthroughs until 2024, it significantly contributes to both the theoretical frameworks and practical applications within its discipline, boasting a strong Scopus ranking of #40/313 in Pharmacology and #56/236 in Immunology, placing it in the top percentiles for its field. Although it does not offer Open Access options, the journal remains an invaluable resource for researchers, professionals, and students committed to unraveling the complexities of inflammation and its implications in health and disease.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

Mucosal Immunology, published by Elsevier Science Inc, is a leading journal dedicated to advancing the field of immunology with a particular focus on mucosal immunity. Since its inception in 2008, the journal has established itself as a premier source of cutting-edge research, evidenced by its impressive Q1 ranking in both Immunology and Allergy for 2023, and its notable positions within the top ranks of Scopus (Rank #21/233 in Immunology and Allergy and Rank #24/236 in Immunology and Microbiology). The journal serves as a vital resource for researchers, professionals, and students aiming to explore the complexities of mucosal immune responses and their implications in health and disease. While it operates under a subscription model, Mucosal Immunology is committed to disseminating quality research globally and enhancing collaborative efforts within the scientific community. Explore the latest findings and connect with influential scholarship in this rapidly evolving field.

CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.